ClinicalTrials.gg
CompletedNCT06751550Asthma FeNOUpdated Jan 8, 2025

Changes in FeNO Value During Pulmonary Rehabilitation in Patients with Asthma

An observational study in Asthma Bronchiale, Asthmatic Patients and Asthmatics, sponsored by Schön Klinik Berchtesgadener Land. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-08.

Sponsored by Schön Klinik Berchtesgadener Land · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
62
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 385 studies in Asthma with a site in Germany — 20 open to participants now, 29 under way, 7 of them phase 3. Asthma · Germany.

Enrollment
34th of 46
62 · median 239
Started
2021
with 12 others
Observational
46 of 385
9 open now
Registered
370th of 385
by date

Among the 385 studies in Asthma with a site in Germany, this one is the 34th largest by enrollment of the 46 observational ones that give a count, is one of 13 that started in 2021, is one of 46 observational ones, and was the 370th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

20 of the 385 studies in Asthma with a site in Germany are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 385 studies in Asthma with a site in Germany, or all of them as a file.
02

Study summary

This study investigates the use of fractional exhaled nitric oxide (FeNO) measurement to monitor non-pharmacological therapy during a three-week inpatient rehabilitation programme for asthma patients. It compares FeNO levels (measured three times a day) with clinical parameters and quality of life to analyse daily fluctuations and the acute effect of exercise training on FeNO levels. As FeNO is a non-invasive biomarker of airway inflammation, this study aims to expand its role in therapy monitoring and explore its application in a rehabilitation setting.

03

Conditions studied

  • Asthma Bronchiale
  • Asthmatic Patients
  • Asthmatics

Browse trials for

Keywords

  • FeNO
  • Fractional Exhaled Nitric Oxide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be recruitet at the pulmonary rehabilitation center at the Schön Klinik Berchtesgadener Land in Schönau am Königssee, Germany

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of bronchial asthma (all disease severities)
  • (COPD) with an asthma component, where the asthma component plays a role
  • written

Exclusion criteria

Exclusion Criteria:

  • (COPD) as the primary disease
  • unability to perform FeNO measurement independently
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
62 participants (actual)
Patient registry
No

Groups and cohorts

  • Asthmatic patients
06

What researchers measure

Primary outcomes

  1. Fractional Exhaled Nitric Oxide (FeNO) at rest

    Measurement of FeNo will be done with the Vivatmo Me device (by Bosch Health Care Solutions GmbH)

    Time frame: From enrollment to the end of rehabilitation at 3 weeks. Daily measurements at 9AM; 1PM; 5PM

  2. Fractional Exhaled Nitric Oxide (FeNO) before/after exercise

    Measurement of FeNo will be done with the Vivatmo Me device (by Bosch Health Care Solutions GmbH)

    Time frame: From enrollment to the end of rehabilitation at 3 weeks, FeNO measurements will be done before and after a bicycle endurance training

Secondary outcomes

  1. Asthma control

    Assessed by Asthma Control Test (ACT)

    Time frame: On admission and discharge from the 3-week rehabilitation programme

  2. Lung function

    Forced expiratory flow in 1 second, will be measured by Bodyplethysmography

    Time frame: On admission and discharge from the 3-week rehabilitation programme

  3. Eosinophils

    Eosinophils will be collected by venous blood sample. Unit: total number of cells per ul blood and percentage

    Time frame: On admission and discharge from the 3-week rehabilitation programme

  4. C-reactive protein

    C-reactive protein will be collected by venous blood sample. Unit: mg/liter

    Time frame: On admission and discharge from the 3-week rehabilitation programme

  5. Immunoglobulin E (IgE)

    Immunoglobulin E will be collected by venous blood sample. Unit: ug/liter

    Time frame: On admission and discharge from the 3-week rehabilitation programme

  6. 6-minute walk test

    This test will be performed according to the described standard of the American Thoracic Society and the European Respiratory Society 2014

    Time frame: On admission and discharge from the 3-week rehabilitation programme

07

Study locations

1 site
  • Schön Klinik Berchtesgadener Land
    Schonau am Konigssee, 83471, Germany
08

References and documents

Individual participant data

Plan to share: Yes — The data will be made available upon personal request.

Supporting information: Study protocol, Informed consent form

Time frame: The data will be made available upon personal request.

Access criteria: The data will be made available upon personal request submitting a proposal that describes planned analyses.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Dec 2024, 43 months.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's 43 months is above that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2024
First posted
Dec 30, 2024
StartActual
May 17, 2021
Primary completionActual
Dec 20, 2024
CompletionActual
Dec 20, 2024
Last update
Jan 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06751550
Lead sponsor
Schön Klinik Berchtesgadener Land
Collaborators
Bosch Healthcare Solutions GmbH
Responsible party
Prof. Dr. Andreas Rembert Koczulla (Professor, Schön Klinik Berchtesgadener Land) — Principal investigator
First posted
Dec 30, 2024
Start date
May 17, 2021
Primary completion
Dec 20, 2024
Completion
Dec 20, 2024
Last update
Jan 8, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion